news & events
portfolio news
24.02.20
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting
14.02.20
Xeltis trials show promising function of living heart valves restored in children
13.02.20
First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
11.02.20
CorWave Appoints Jim Schuermann as an Independent Director
06.02.20
Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer
09.01.20
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
07.01.20
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
07.01.20
Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer
04.12.19
Anaconda biomed secures €20 million round of funding
05.11.19
Anaconda biomed announces first-in-human study of Next-generation thrombectomy system
